AlphAIAlphAI — Financial news for AI agents
haaretz.comOCT 101 min read$TEVA

Second U.K. Health Body Drops Israeli Drugmaker Teva After Pro-Palestinian Pressure

Two U.K. health bodies have ended partnerships with Teva Pharmaceuticals due to pro-Palestinian pressure, following similar actions by other organizations. The move was encouraged by an NHS doctor who criticized the continued financial ties.

Original reporting
haaretz.com
Published Oct 10, 2026, 7:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 8:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Second U.K. Health Body Drops Israeli Drugmaker Teva After Pro-Palestinian Pressure — source image
Source · haaretz.com
Decision brief

The 30-second read

$TEVABearishMed
01

Why it matters

The removal may trigger a sell‑off in TEVA shares and prompt reassessment of exposure to geopolitical risk.

02

Market read

Regulatory delisting could depress TEVA stock and affect sector sentiment toward pharma firms operating in politically volatile regions.

03

What to watch

Possible compensating demand in other markets may offset UK losses.

Relevance 7/10Novelty 7/10Timing: immediate

Background

The article reports a regulatory action by a UK health body against Teva, reflecting heightened political sensitivities.

Company-level read

Ticker impact

$TEVABearishHigh confidence
Context

A UK health authority removed Teva from its approved supplier list due to pro-Palestinian pressure.

Expected impact

likely downward pressure as investors price in lost contracts

Evidence & confidence

Regulatory removal directly affects revenue potential and signals broader reputational risk.

Market effects

Sector

Potential scrutiny of other pharma suppliers in politically sensitive regions.

Regional

UK healthcare procurement may shift toward alternative vendors.

Global

May influence investor sentiment toward companies with exposure to Middle East geopolitics.

Counterpoint

What could challenge this read

The impact could be limited if Teva quickly secures alternative UK contracts.

Key entities

  • Company
    Teva Pharmaceutical Industries Ltd.

    Israeli drugmaker listed on NYSE as TEVA.

  • Regulatory Agency
    UK Health Body

    Unspecified UK health authority that dropped Teva from its supplier list.

Read at source← All news

Related articles

OCT 13
$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

lifesciencesweden.se1 min
OCT 13
$TEVAHigh

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

medicaldialogues.in2 min
OCT 12
$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

drugtopics.com3 min
OCT 12
$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

pharmacytimes.com3 min
OCT 12
$TEVAMed

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.

zacks.com6 min